

Docket No. 258087US0X PCT

10/506334 #3  
DY09 PCT/PTO 02 SEP 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Boris LINARD, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/FR03/00698

GAU:

FILED: Herewith

EXAMINER:

FOR: PEPTIDES FOR USE IN ANTITUMOR IMMUNOTHERAPY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS  
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the International Search Report and listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. In accordance with discussions on August 4, 2004 with Mr. Nicholas P. Godici, Commissioner for Patents, it is no longer required to submit copies of cited pending applications. A modification of the Rules will be published soon in the Official Gazette. Cited issued patents, if any, are listed on the attached PTO form 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,  
MAIER & NEUSTADT, P.C.



Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000  
Fax. (703) 413-2220  
(OSMMN 05/03)

Surinder Sachar

Registration No. 34,423

DT09 REC'D STARTED 02 SEP 2004

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 258087US0X PCT		SERIAL NO. New U.S. PCT Application Based on PCT/FR03/00698	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Francine JOTEREAU, et al.		10/506334	
				FILING DATE Herewith		GROUP	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	01/90197	11/29/01	WO			NO
	AP	01/16320	03/08/01	WO			NO
	AQ	00/21551	04/20/00	WO			NO
	AR	01/53833	07/26/01	WO			NO
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	ROMERO, P. et al. "Therapeutic cancer vaccines based on molecularly defined human tumor antigens", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB. vol.20, pages A2-A7, XP004397465, ISSN: 0264-410X 12/19/2002					
	AX	MENDEZ, R et al. "Analysis of HLA class I expression in different metastases from two melanoma patients undergoing peptide immunotherapy." TISSUE ANTIGENS. DENMARK, vol.57, no.6, pages 508-519, XP002265728 ISSN: 0001-2815 06/2001					
	AY	VALMORI, D. et al. "Diversity of the Fine Specificity Displayed by HLA-A*0201-Restricted CTL Specific for the Immunodominant Melan-A/MART-1 Antigenic Peptide," Journal of Immunology, The Williams and Wilkins Co. Baltimore, US, vol.161, no.12, pages 6956-6962 XP00086281, ISSN: 0022-1767 1998					
	AZ	BENLALAM, H. et al. "Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy." European Journal of Immunology. Germany, vol. 31, no. 7, pages 2007-2015, XP002265727, ISSN: 0014-2980 07-2001				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							